Treatments | Number of revertants(M ± SD)/ plate and %; of inhibition | |||||||
---|---|---|---|---|---|---|---|---|
HK | TA 98 | TA 100 | ||||||
μg/plate | − S9 | %; inhibition | + S9 | %; inhibition | − S9 | %; inhibition | + S9 | %; inhibition |
Ctrol + | NOPD | B[a]P | SA | AFB 1 | ||||
638 + 30 | 1244 + 38 | 1219 + 46 | 1607 + 79 | |||||
9.7 | 525 + 7 | 18* | 874 + 21 | 31** | 1139 + 20 | 7* | 1183 + 30 | 30** |
19.5 | 507 + 15 | 21* | 869 + 4 | 32** | 1112 + 34 | 9* | 976 + 18 | 45*** |
39.0 | 477 + 5 | 26** | 813 + 18 | 36** | 1169 + 32 | 5* | 943 + 11 | 47*** |
58.5 | 521 + 9 | 19* | 618 + 6 | 52*** | 1145 + 16 | 7* | 612 + 33 | 71*** |
78.0 | 480 + 16 | 25** | 539 + 32 | 59*** | 1181 + 41 | 3* | 354 + 22 | 89*** |
TA 102 | TA 97a | |||||||
μg/plate | - S9 | %; inhibition | + S9 | %; inhibition | - S9 | %; inhibition | + S9 | %; inhibition |
Ctrol + | MMC | 2-AF | NOPD | 2-AA | ||||
1184 + 42 | 1279 + 12 | 884 + 34 | 1083 + 67 | |||||
9.7 | 1236 + 17 | - | 852 + 21 | 42*** | 934 + 33 | - | 682 + 52 | 43*** |
19.5 | 1201 + 23 | - | 855 + 22 | 42*** | 948 + 24 | - | 659 + 41 | 45*** |
39.0 | 1317 + 14 | - | 820 + 19 | 46*** | 979 + 84 | - | 628 + 16 | 49*** |
58.5 | 1017 + 56 | 18* | 754 + 9 | 52*** | 1006 + 54 | - | 456 + 13 | 67*** |
78.0 | 979 + 51 | 22* | 757 + 29 | 52*** | 1026 + 75 | - | 523 + 86 | 60*** |